Related Experiment Video

Updated: Sep 21, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

Comparison of different decision support software programs in perspective of potential drug-drug interactions in the

Muhammed Yunus Bektay1,2, Zehra Seker3, Hatice Kubra Eke4

  • 1Department of Clinical Pharmacy, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|June 1, 2022
PubMed
Abstract

Insights

Cancer patients face significant risks from drug-drug interactions (DDIs). This study found major differences in how cancer decision support software (CDSS) identifies potential DDIs, highlighting a need for improved validation.

Area of Science:

  • Oncology
  • Clinical Pharmacy
  • Health Informatics

Background:

  • Drug-drug interactions (DDIs) contribute to 20-30% of adverse events.
  • Cancer patients are at higher risk for DDIs due to polypharmacy with chemotherapeutic agents.
  • Identifying and managing potential DDIs is crucial for patient safety in cancer care.

Purpose of the Study:

  • To compare the performance of different clinical decision support software (CDSS) programs in identifying potential drug-drug interactions (pDDIs) in cancer patients.
  • To evaluate the discrepancies in pDDI detection and severity assessment among various CDSS.

Main Methods:

  • A cross-sectional study involving 231 cancer patients.
  • Clinical pharmacists assessed patient treatment regimens.
  • Potential DDIs were evaluated using three distinct CDSS: Lexicomp®, Medscape®, and Micromedex®.

Main Results:

  • Lexicomp® identified the highest pDDI ratio (19.50%), followed by Micromedex® (11.15%) and Medscape® (7.09%).
  • Significant variations in the number and severity of pDDIs were observed across the evaluated CDSS.
  • Common pDDIs included diclofenac/dexamethasone and escitalopram/granisetron, with differing recommendations from each CDSS.

Conclusions:

  • Substantial disparities exist in the detection and reporting of pDDIs among different CDSS.
  • The findings underscore the issue of suboptimal prescribing in cancer care.
  • Regulatory bodies should implement and verify robust validation and reporting mechanisms for CDSS.
Keywords:
Drug–drug interactionclinical decision support softwareclinical pharmacistoncology

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K
Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.6K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
616
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.4K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.9K
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
296
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
463